期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 142, 期 6, 页码 2760-2765出版社
AMER CHEMICAL SOC
DOI: 10.1021/jacs.9b12940
关键词
-
资金
- J1 Biotech Co., Ltd.
- National Key R&D Program of China [2018YFA0900400]
- National Natural Science Foundation of China [31670090, 31800032]
- Medical Science Advancement Program (Clinical Medicine) of Wuhan University [TFLC2018002]
Herein, we report a short semisynthesis of the potent transient receptor potential canonical (TRPC) channel agonist englerin A (EA) and the related guaianes oxyphyllol and orientalol E. The guaia-6,10(14)-diene starting material was systematically engineered in Escherichia coli and Saccharomyces cerevisiae using the CRISPR/Cas9 system and was produced with high titers. The potentially scalable approach combines the advantages of synthetic biology and chemical synthesis providing an efficient and economical method for producing EA and analogues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据